Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 4/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18546000 | 0.91 | ALDH1A1 (0.56) | ALDH1A1KMT2ATSHRHSP90AA1MAPT | |
| SCHEMBL22722163 | 0.91 | ALDH1A1 (0.69) | ALDH1A1KMT2ATSHRHSP90AA1MAPT | |
| SCHEMBL18545992 | 0.84 | ALDH1A1 (0.61) | ALDH1A1KMT2ATSHRHSP90AA1MAPT | |
| SCHEMBL20373153 | 0.81 | TP53 (0.62) | ALDH1A1KMT2ATSHRHSP90AA1MAPT | |
| SCHEMBL18546039 | 0.81 | TP53 (0.69) | ALDH1A1KMT2AHSP90AA1MAPTGAA | |
| SCHEMBL22722166 | 0.80 | ALDH1A1 (0.63) | ALDH1A1KMT2ATSHRHSP90AA1MAPT | |
| SCHEMBL22722167 | 0.79 | ALDH1A1 (0.62) | ALDH1A1KMT2ATSHRHSP90AA1MAPK1 | |
| SCHEMBL18546049 | 0.79 | ALDH1A1 (0.63) | ALDH1A1KMT2AHSP90AA1MAPTGAA | |
| SCHEMBL18545997 | 0.78 | HSP90AA1 (0.79) | ALDH1A1KMT2AHSP90AA1MAPTGAA | |
| SCHEMBL18545995 | 0.77 | TSHR (0.58) | ALDH1A1KMT2ATSHRMAPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10851051-B2 | Compositions and methods for treating multiple myeloma | THE BROAD INSTITUTE, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| WO-2017030987-A9 | COMPOSITIONS AND METHODS FOR TREATING MULTIPLE MYELOMA | THE BROAD INSTITUTE, INC. (US) | 2018-07-12 | — | — | WO | disclosed |
| WO-2017030987-A1 | COMPOSITIONS AND METHODS FOR TREATING MULTIPLE MYELOMA | THE BROAD INSTITUTE, INC. (US) | 2017-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10851051-B2 | Compositions and methods for treating multiple myeloma | BRIX1, UBQLN1, PRTN3 | ALDH1A1 3468/4885KMT2A 1556/4885TSHR 3904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.